Universal Beteiligungs und Servicegesellschaft mbH Purchases 83,003 Shares of Scholar Rock Holding Corporation $SRRK

Universal Beteiligungs und Servicegesellschaft mbH lifted its position in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) by 108.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 159,741 shares of the company’s stock after acquiring an additional 83,003 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Scholar Rock were worth $5,949,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Moody Aldrich Partners LLC boosted its holdings in shares of Scholar Rock by 53.5% in the 3rd quarter. Moody Aldrich Partners LLC now owns 101,742 shares of the company’s stock valued at $3,789,000 after purchasing an additional 35,481 shares in the last quarter. Voya Investment Management LLC lifted its position in shares of Scholar Rock by 18.1% during the 3rd quarter. Voya Investment Management LLC now owns 443,155 shares of the company’s stock worth $16,503,000 after buying an additional 67,839 shares during the last quarter. Norges Bank acquired a new stake in Scholar Rock in the second quarter valued at about $41,628,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. grew its position in Scholar Rock by 145.3% in the second quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. now owns 769,442 shares of the company’s stock valued at $27,254,000 after acquiring an additional 455,753 shares during the last quarter. Finally, American Century Companies Inc. raised its stake in Scholar Rock by 4.3% during the second quarter. American Century Companies Inc. now owns 692,676 shares of the company’s stock worth $24,535,000 after acquiring an additional 28,749 shares in the last quarter. Institutional investors and hedge funds own 91.08% of the company’s stock.

Scholar Rock Stock Performance

NASDAQ:SRRK opened at $44.89 on Tuesday. Scholar Rock Holding Corporation has a 52-week low of $22.71 and a 52-week high of $48.28. The firm has a market cap of $4.58 billion, a price-to-earnings ratio of -14.25 and a beta of 0.63. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.30 and a current ratio of 6.30. The business’s fifty day moving average is $43.89 and its 200 day moving average is $37.37.

Scholar Rock (NASDAQ:SRRK) last posted its earnings results on Friday, November 14th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.02). During the same period last year, the firm posted ($0.66) earnings per share. Research analysts predict that Scholar Rock Holding Corporation will post -2.42 EPS for the current year.

Insider Buying and Selling

In other news, insider Mo Qatanani sold 14,898 shares of the stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $46.71, for a total transaction of $695,885.58. Following the completion of the sale, the insider owned 85,660 shares of the company’s stock, valued at approximately $4,001,178.60. This represents a 14.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Junlin Ho sold 8,016 shares of the stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $44.48, for a total transaction of $356,551.68. Following the sale, the general counsel owned 214,553 shares of the company’s stock, valued at approximately $9,543,317.44. This represents a 3.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 305,687 shares of company stock worth $13,540,573 in the last 90 days. 13.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on SRRK shares. JPMorgan Chase & Co. lifted their price target on shares of Scholar Rock from $46.00 to $47.00 and gave the company an “overweight” rating in a report on Tuesday, November 18th. HC Wainwright increased their price objective on Scholar Rock from $44.00 to $58.00 and gave the company a “buy” rating in a report on Monday. Barclays raised their price target on shares of Scholar Rock from $45.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. Wolfe Research assumed coverage on Scholar Rock in a research note on Tuesday, November 18th. They issued an “outperform” rating and a $42.00 price target on the stock. Finally, Citigroup began coverage on shares of Scholar Rock in a research report on Friday, January 9th. They set a “buy” rating and a $55.00 price objective on the stock. Four investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $51.14.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).